Status:
COMPLETED
Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia
Lead Sponsor:
Lund University
Collaborating Sponsors:
Swedish International Development Cooperation Agency (SIDA)
Swedish Agency for Civil Contingencies
Conditions:
HIV Infection
Tuberculosis
Eligibility:
All Genders
18+ years
Brief Summary
Background: Tuberculosis (TB) and HIV are leading causes of disease and death in Subsaharan Africa. Antiretroviral therapy (ART) dramatically improves prognosis in HIV infection, but TB is still a com...
Detailed Description
Tuberculosis (TB) remains as the leading opportunistic infection and cause of death among HIV-infected subjects in resource-limited settings (1). The management of TB-HIV co-infection constitutes a gr...
Eligibility Criteria
Inclusion
- Diagnosis of tuberculosis
- Not having received TB treatment for more than two weeks
- Consent to HIV testing
Exclusion
- Previous or ongoing antiretroviral therapy
- TB treatment within the preceding six months
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT01252537
Start Date
September 1 2010
End Date
January 1 2014
Last Update
April 23 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Adama Health Centre
Ādama, Oromiya, Ethiopia
2
Bishoftu hospital
Bishoftu, Oromiya, Ethiopia
3
Dukem Health Centre
Dukem, Oromiya, Ethiopia
4
Mojo Health Centre
Mojo, Oromiya, Ethiopia